Skip to main content

Compare Stocks

Date Range: 

 BioMarin PharmaceuticalElanco Animal HealthZai LabOno PharmaceuticalGrifols
SymbolNASDAQ:BMRNNYSE:ELANNASDAQ:ZLABOTCMKTS:OPHLFNASDAQ:GRFS
Price Information
Current Price$75.60$32.10$145.56$23.80$18.12
52 Week RangeBuyBuyBuyN/ABuy
MarketRank™
Overall Score2.11.81.60.91.3
Analysis Score4.32.33.50.00.0
Community Score3.12.22.42.22.1
Dividend Score0.00.00.00.01.7
Ownership Score1.72.51.70.00.0
Earnings & Valuation Score1.31.90.62.52.5
Analyst Ratings
Consensus RecommendationBuyHoldBuyN/ABuy
Consensus Price Target$118.20$32.23$197.85N/AN/A
% Upside from Price Target56.35% upside0.40% upside35.92% upsideN/AN/A
Trade Information
Market Cap$13.82 billion$15.18 billion$13.78 billion$13.42 billion$12.83 billion
Beta0.710.860.951.060.59
Average Volume1,200,3653,885,239494,3552,767848,847
Sales & Book Value
Annual Revenue$1.70 billion$3.07 billion$12.98 million$2.69 billion$5.71 billion
Price / Sales8.114.941,061.814.552.18
Cashflow$0.58 per share$1.95 per shareN/A$1.09 per share$1.56 per share
Price / Cash130.2216.48N/A21.9211.58
Book Value$17.38 per share$14.87 per share$5.07 per share$10.16 per share$11.15 per share
Price / Book4.352.1628.712.341.63
Profitability
Net Income$-23,850,000.00$67.90 million$-195,070,000.00$549.28 million$700.16 million
EPS$0.07$1.06($3.03)$1.09$1.17
Trailing P/E Ratio17.30N/AN/A21.6416.18
Forward P/E Ratio142.6435.67N/A14.6012.00
P/E Growth3.894.13N/AN/A1.30
Net Margins45.74%-8.45%N/A22.14%12.79%
Return on Equity (ROE)4.34%3.43%N/A11.29%10.65%
Return on Assets (ROA)2.84%2.04%N/A9.71%4.79%
Dividend
Annual PayoutN/AN/AN/AN/A$0.14
Dividend YieldN/AN/AN/AN/A0.77%
Three-Year Dividend GrowthN/AN/AN/AN/A-49.65%
Payout RatioN/AN/AN/AN/A11.97%
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.26%0.67%N/AN/A0.95%
Current Ratio3.20%1.75%8.57%2.78%2.93%
Quick Ratio2.38%0.90%8.46%2.33%1.33%
Ownership Information
Institutional Ownership Percentage97.65%86.83%81.32%N/A15.15%
Insider Ownership Percentage2.15%0.12%N/AN/AN/A
Miscellaneous
Employees3,05910,2001,1943,56024,000
Shares Outstanding182.74 million473.00 million94.69 million514.12 million687.55 million
Next Earnings Date8/3/2021 (Estimated)7/29/2021 (Estimated)N/AN/A7/29/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
Plasma Expander Market 2021 Overview, Opportunities, In-Depth Analysis by 2027 : Grifols USA, LLC, Astrazeneca, Abbott, CSL Behring, Novartis, BioTime, Kedrion Biopharma Inc., Abbott, Biogen Idec – Test & Measurement - Test & MeasurementPlasma Expander Market 2021 Overview, Opportunities, In-Depth Analysis by 2027 : Grifols USA, LLC, Astrazeneca, Abbott, CSL Behring, Novartis, BioTime, Kedrion Biopharma Inc., Abbott, Biogen Idec – Test & Measurement - Test & Measurement
testmeasurement.com.au - May 12 at 3:50 PM
$0.31 Earnings Per Share Expected for Grifols, S.A. (NASDAQ:GRFS) This Quarter$0.31 Earnings Per Share Expected for Grifols, S.A. (NASDAQ:GRFS) This Quarter
americanbankingnews.com - May 12 at 1:16 PM
Global Blood Transfusion Market 2021 to 2026 Growth Forecast: B.Braun, TERUMO, Grifols, Fresenius Kabi – The Manomet Current - The Manomet CurrentGlobal Blood Transfusion Market 2021 to 2026 Growth Forecast: B.Braun, TERUMO, Grifols, Fresenius Kabi – The Manomet Current - The Manomet Current
manometcurrent.com - May 12 at 10:50 AM
ChinaHuman Serum Albumin Markets Report 2021: In 2020, Annual Growth Rate was 11.3%, A Slow Down Compared to that in 2019 Due to the COVID-19 Epidemic - Forecast to 2025 - Yahoo FinanceChina'Human Serum Albumin Markets Report 2021: In 2020, Annual Growth Rate was 11.3%, A Slow Down Compared to that in 2019 Due to the COVID-19 Epidemic - Forecast to 2025 - Yahoo Finance
finance.yahoo.com - May 12 at 10:50 AM
Global Plasma Fractionation Market 2021 Overview, Opportunities, In-Depth Analysis by 2027 : RAAS, Octapharma, Biotest, BPL, Hualan Bio, Takeda, Kedrion, CSL Behring, LFB Group, Grifols, CBPO – Brockville Observer - Brockville ObserverGlobal Plasma Fractionation Market 2021 Overview, Opportunities, In-Depth Analysis by 2027 : RAAS, Octapharma, Biotest, BPL, Hualan Bio, Takeda, Kedrion, CSL Behring, LFB Group, Grifols, CBPO – Brockville Observer - Brockville Observer
thebrockvilleobserver.ca - May 12 at 10:50 AM
MAY E-NEWSLETTER: PRIORITIZE YOUR HEALTH THIS MAY | Blood Clots - National Blood Clot AllianceMAY E-NEWSLETTER: PRIORITIZE YOUR HEALTH THIS MAY | Blood Clots - National Blood Clot Alliance
stoptheclot.org - May 11 at 6:30 PM
Grifols has an urgent need for Plasma donations - ABC 4Grifols has an urgent need for Plasma donations - ABC 4
abc4.com - May 11 at 6:30 PM
Parenteral Nutrition Products Market Quality & Quantity Analysis | Baxter International, Hospira, B. Braun Melsungen, Grifols International, Fresenius Kabi – The Manomet Current - The Manomet CurrentParenteral Nutrition Products Market Quality & Quantity Analysis | Baxter International, Hospira, B. Braun Melsungen, Grifols International, Fresenius Kabi – The Manomet Current - The Manomet Current
manometcurrent.com - May 11 at 8:17 AM
Investigation Report on Chinas Human Serum Albumin Markets, 2016-2020 & 2021-2025 - ResearchAndMarkets.com - Galveston County Daily NewsInvestigation Report on China's Human Serum Albumin Markets, 2016-2020 & 2021-2025 - ResearchAndMarkets.com - Galveston County Daily News
galvnews.com - May 10 at 9:08 PM
Thrombin (Human) Market Development And Trends Forecasts 2021-2027:Shanghai RAAS, Grifols, Octapharma, Hualan Biological, Baxter, Bayer, CSL – Test & Measurement - Test & MeasurementThrombin (Human) Market Development And Trends Forecasts 2021-2027:Shanghai RAAS, Grifols, Octapharma, Hualan Biological, Baxter, Bayer, CSL – Test & Measurement - Test & Measurement
testmeasurement.com.au - May 10 at 9:08 PM
Investigation Report on Chinas Human Serum Albumin Markets, 2016-2020 & 2021-2025 - ResearchAndMarkets.com - Business WireInvestigation Report on China's Human Serum Albumin Markets, 2016-2020 & 2021-2025 - ResearchAndMarkets.com - Business Wire
businesswire.com - May 10 at 3:55 PM
Prolastin Market R & D including top key players Grifols – Brockville Observer - Brockville ObserverProlastin Market R & D including top key players Grifols – Brockville Observer - Brockville Observer
thebrockvilleobserver.ca - May 10 at 8:36 AM
Human Hyperimmune Globulins Market 2021 Is Booming Worldwide | Key Players:CSLBehring,Grifols,Biotest,Kedrion,CBPO – Lakes Business News - Lakes Business NewsHuman Hyperimmune Globulins Market 2021 Is Booming Worldwide | Key Players:CSLBehring,Grifols,Biotest,Kedrion,CBPO – Lakes Business News - Lakes Business News
lakesbusinessnews.com - May 10 at 8:36 AM
Colloids (Blood Plasma) Market 2021-2029 Global Analysis : CSL Behring, Baxter, Grifols, Octapharma – Clark County Blog - Clark County BlogColloids (Blood Plasma) Market 2021-2029 Global Analysis : CSL Behring, Baxter, Grifols, Octapharma – Clark County Blog - Clark County Blog
clarkcountyblog.com - May 8 at 6:45 PM
Global Hyperimmune Serum Market 2021 Industry Scope – CSL Behring, Grifols, Biotest, Kedrion, CBPO – FLA News - FLA NewsGlobal Hyperimmune Serum Market 2021 Industry Scope – CSL Behring, Grifols, Biotest, Kedrion, CBPO – FLA News - FLA News
flanewsonline.com - May 7 at 9:28 AM
azValor Asset Management Buys - GuruFocus.comazValor Asset Management Buys - GuruFocus.com
gurufocus.com - May 6 at 6:26 PM
Grifols: Q1 Earnings Snapshot - CT PostGrifols: Q1 Earnings Snapshot - CT Post
ctpost.com - May 6 at 6:26 PM
Grifols (NASDAQ:GRFS) Announces  Earnings ResultsGrifols (NASDAQ:GRFS) Announces Earnings Results
americanbankingnews.com - May 6 at 6:06 PM
Analysts Conflicted on These Healthcare Names: Grifols SA (GRFS) and Genfit SA (GNFT) - Smarter AnalystAnalysts Conflicted on These Healthcare Names: Grifols SA (GRFS) and Genfit SA (GNFT) - Smarter Analyst
smarteranalyst.com - May 6 at 3:25 AM
Grifols: Q1 Earnings Snapshot - San Antonio Express-NewsGrifols: Q1 Earnings Snapshot - San Antonio Express-News
expressnews.com - May 6 at 3:25 AM
Grifols: Q1 Earnings Snapshot - The Edwardsville IntelligencerGrifols: Q1 Earnings Snapshot - The Edwardsville Intelligencer
theintelligencer.com - May 5 at 5:24 PM
Grifols reduces its profit by 30% in the first quarter of 2021, to 129.9 million - Born2InvestGrifols reduces its profit by 30% in the first quarter of 2021, to 129.9 million - Born2Invest
born2invest.com - May 5 at 11:48 AM
Medical Consumables Market May See Big Move | TERUMO, Fresenius, Grifols – The Shotcaller - The ShotcallerMedical Consumables Market May See Big Move | TERUMO, Fresenius, Grifols – The Shotcaller - The Shotcaller
theshotcaller.net - May 5 at 11:48 AM
Should You Buy Grifols SA - ADR ADR Class B (GRFS) Stock Tuesday? - InvestorsObserverShould You Buy Grifols SA - ADR ADR Class B (GRFS) Stock Tuesday? - InvestorsObserver
investorsobserver.com - May 4 at 6:40 PM
Grifols ADR Earnings, Revenue Miss in Q1 By Investing.com - Investing.comGrifols ADR Earnings, Revenue Miss in Q1 By Investing.com - Investing.com
investing.com - May 4 at 6:40 PM
Grifols (NASDAQ:GRFS) Stock Rating Reaffirmed by Berenberg BankGrifols (NASDAQ:GRFS) Stock Rating Reaffirmed by Berenberg Bank
marketbeat.com - April 27 at 4:37 PM
3 Health Care Stocks That Could Double by Year End3 Health Care Stocks That Could Double by Year End
marketbeat.com - February 11 at 10:50 AM
DateCompanyBrokerageAction
4/28/2021BioMarin PharmaceuticalWedbushReiterated Rating
4/26/2021BioMarin PharmaceuticalCredit Suisse GroupInitiated Coverage
4/26/2021BioMarin PharmaceuticalMorgan StanleyLower Price Target
3/8/2021BioMarin PharmaceuticalEvercore ISIUpgrade
3/8/2021BioMarin PharmaceuticalCanaccord GenuityLower Price Target
3/1/2021BioMarin PharmaceuticalRobert W. BairdReiterated Rating
11/6/2020BioMarin PharmaceuticalSVB LeerinkLower Price Target
9/10/2020BioMarin PharmaceuticalTruistLower Price Target
8/20/2020BioMarin PharmaceuticalOppenheimerLower Price Target
8/20/2020BioMarin PharmaceuticalJefferies Financial GroupLower Price Target
8/20/2020BioMarin PharmaceuticalWilliam BlairReiterated Rating
8/19/2020BioMarin PharmaceuticalCitigroupDowngrade
8/19/2020BioMarin PharmaceuticalRoyal Bank of CanadaDowngrade
8/19/2020BioMarin PharmaceuticalStifel NicolausDowngrade
5/11/2021Elanco Animal HealthG.ResearchUpgrade
5/11/2021Elanco Animal HealthGabelliUpgrade
5/11/2021Elanco Animal HealthBarclaysUpgrade
3/22/2021Elanco Animal HealthRaymond JamesReiterated Rating
12/9/2020Elanco Animal HealthArgusDowngrade
11/17/2020Elanco Animal HealthCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
8/4/2020Elanco Animal HealthThe Goldman Sachs GroupInitiated Coverage
7/27/2020Elanco Animal HealthCleveland ResearchDowngrade
7/20/2020Elanco Animal HealthBank of AmericaBoost Price Target
4/13/2021Zai LabGuggenheimBoost Price Target
11/16/2020Zai LabJPMorgan Chase & Co.Boost Price Target
9/4/2019Zai LabChina Renaissance SecuritiesInitiated Coverage
7/5/2019Zai LabMacquarieInitiated Coverage
4/27/2021GrifolsBerenberg BankReiterated Rating
4/20/2021GrifolsDeutsche Bank AktiengesellschaftInitiated Coverage
3/17/2021GrifolsHSBCUpgrade
(Data available from 5/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.